Any severe or poorly controlled systemic disease (e.g., hypertension; clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound healing, ulcer or bone fracture)
45.0
Other clinically significant disorders such as:* Active infection requiring systemic treatment within 28 days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; participants with known hepatitis B infection should be screened for active disease prior to study participation; participants with known hepatitis C infection must not be actively receiving treatment for the infection* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment* History of organ transplant* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment* History of major surgery as follows:** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
42.0
Other clinically significant disorders such as:* Active uncontrolled infection requiring intravenous systemic treatment within 14 days before the first dose of study treatment* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment* History of organ transplant* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment* History of major surgery as follows:** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications*** In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
72.0
Evidence of clinically significant bleeding diathesis or underlying coagulopathy, non-healing wound
57.0
Serious or non-healing wound, ulcer or bone fracture
23.0
History of serious or non-healing wound, ulcer, or bone fracture
340.0
Other clinically significant disorders such as:* Severe active infection requiring systemic treatment within 28 days before the first dose of study treatment* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment* History of organ transplant* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)* History of major surgery as follows:** Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and Mediport placement* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
135.0
Patients who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment are not eligible
67.0
No history of serious non-healing wound, ulcer, or bone fractures
130.0
Non-healing wound, ulcer or bone fracture
84.0
At least 4 weeks must have elapsed since any surgeries, with evidence of completed wound healing
24.0
At least 4 weeks must have elapsed since any surgeries, with evidence of good wound healing
28.0
Patients with a non-healing wound, fracture, or ulcer
132.0
Serious or non-healing wound, active ulcer or bone fracture
22.0
History of serious or non-healing wound, ulcer, or bone fracture
40.0
Serious or non-healing wound, ulcer or bone fracture
98.0